|
Dear Colleagues,
The First International Congress on Clinical Neurology and Epidemiology (Neuroepidemiology) scheduled to take place in Munich, Germany in August 27-30, 2009 is a unique congress for many reasons.
Neuroepidemiology has been perceived for a long time as a science of incidence, prevalence, risk factors, natural history and prognosis of neurological disorders. However, it is only one part of neuroepidemiology called non-experimental neuroepidemiology. The other integral, but commonly forgotten, part of neuroepidemiology is an experimental neuroepidemiology, a research based on clinical trials of effectiveness or efficacy of various interventions in neurological disorders.
This International Congress, for the first time, will bring together scientists and experts in all major fields of experimental and non-experimental neuroepidemiology. Thus, this will be the first entirely clinical congress specifically (and uniquely) devoted to the prevention, epidemiology and management of neurological disorders in human populations. Bringing together neuroepidemiologists, practitioners,
public health physicians and health care policy makers will bridge the gap not
only between trialists and non-experimental neuroepidemiologists but also
between academicians and practicing physicians, thus facilitating the
implementation of most effective, evidence-based treatment, rehabilitation and
preventative strategies of neurological disorders.
Combining scientific sessions in these two interrelated fields of neuroepidemiology with two corresponding half-day teaching courses and a one year-free on-line subscription to the journal of Neuroepidemiology for all registered participants are additional unique features of the Congress.
The main topics of the Congress that will be addressed during plenary, platform and poster sessions include stroke, TIA, dementia, Parkinson’s disease, multiple sclerosis, epilepsy, migraine, traumatic brain injury, peripheral neuropathy, neuromuscular disorders, central nervous system infections and tumours, neurological aspects of aging, neuropsychology and neuropsychiatric disorders. We also plan Satellite Symposia that will be complementary to the main topics of the Congress. The Congress features internationally recognized invited speakers, platform lectures, oral presentations and poster sessions, and will provide an ideal platform for continuing education in all fields of experimental and non-experimental clinical neuroepidemiology.
We hope that this International Congress will provide an excellent opportunity for many neurologists, neurosurgeons, epidemiologists, neuropsychologists, rehabilitation specialists, geriatricians, nurses, aged care specialists and health care providers working in the area of experimental and non-experimental epidemiology of neurological disorders to share their ideas, research findings and experience.
Munich – the Bavarian state capital, third largest city in Germany, is an economic hub and leisure centre, a fountain for the joy of life, a focal point of art and culture, and crossroads of history and modern times. Munich is an architectural synthesis of the arts encompassing impressive examples of building during various epochs of style, from Gothic through Renaissance to Art Nouveau and Art Deco. Modern accents are set by the glass and steel constructions of contemporary architecture, such as the Olympic tent roof and the high-rise buildings of corporate headquarters.
On behalf of the Local Organising Committee of the Congress, we are delighted to welcome you to Munich in August 2009.
Yours sincerely,
Prof. Valery L. Feigin, MD, PhD, FAAN Prof. Dr. Michael G. Hennerici, MD, PhD FAAN
Congress Chairman Congress President
|
